CURRENT RESEARCH TOPICS IN PHARMACY: Microbiology Debates

December 14th, 2022 14.00 PM ISTANBUL

FOR REGISTRATION:

First Session- Moderator: Büşra ERTAŞ 14.00-15.45 PM

Welcome- Assoc.Prof. Esra TATAR

Bacteriotherapy – Dr. Zahraa AMER HASHIM
Mosul University, Mosul, Iraq

Antibiotic resistance – Assist.Prof. Pervin RAYAMAN
Marmara University, Istanbul, Turkey

The vaccination in Albania: An assessment of the level of knowledge and behaviour of the population regarding vaccines.- Assoc.Prof. Mirela MIRAÇI
University of Medicine, Tirana, Albania

Chicken contamination with thermotolerant Campylobacter in Tunisia: Antibiotic resistance and virulence profiling – Dr.Awatf BEJAOUI
Institut Pasteur de Tunis, Tunis, Tunisia

Second Session- Moderator: Esra TATAR 16.00-17.45 PM

Plant phenolics and their synthetic derivatives as inhibitors of Helicobacter pylori: Suggestion for a new mechanism of action - Assoc.Prof. Simone CARRADORI
“G. d’Annunzio” University of Chieti-Pescara University, Chieti Italy

Pomegranate rind extract with Zn (II) combination as a new therapeutic agent for oral care products- Dr.Vildan ÇELİKSOY
Cardiff University, Cardiff, UK

The antimicrobial effects of honey and other bee-derived products- Dr.Saira KHAN
Cardiff University, Cardiff, UK

Chair
Prof. Hatice Kübra ELÇİOĞLU

Vice Chairs
Prof. Levent KABASAKAL & Assoc. Prof. Esra TATAR

ORGANIZING & SCIENTIFIC COMMITTEE
Editorial Board of Journal of Research in Pharmacy
https://www.jrespharm.com/
CURRENT RESEARCH TOPICS IN PHARMACY:
Microbiology Debates

December 14th, 2022 14.00 PM ISTANBUL

ORGANIZING & SCIENTIFIC COMMITTEE
Editorial Board of Journal of Research in Pharmacy
https://www.jrespharm.com/

Euras Tatar
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Turkey
Levent Kabasakal
(Vice Chair of Organizing Committee)
Marmara University, Istanbul, Turkey
Ayşe Nur Hazar Yavuz
(Secretary)
Marmara University, Istanbul, Turkey
Abdulkarim Mohammad Abdi
Yeditepe University, Istanbul, Turkey
Atifa Büşra Uğur Kaplan
Akadimik University, Erzurum, Turkey
Ahmet Ertem
Ege University, Izmir, Turkey
Ali Demir Sezar
Marmara University, Istanbul, Turkey
Ammad Ahmad Farooq
Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan

Ani V. Pajić
University of Naples, Naples, Italy
Annalisa Chiavari
G. d’Annunzio University of Chieti-Pescara, Chieti, Italy
Antoaneta Trendafilova
Bulgarian Academy of Sciences, Sofia, Bulgaria
Ayfer Beceren
Marmara University, Istanbul, Turkey
Ayşe Erol Karalag
Istanbul Medipol University, Istanbul, Turkey
Ayşe Güney Aydın
Bekzade Kafkak University, Istanbul, Turkey
Bahadir Bülbül
Düzce University, Düzce, Turkey
Betül Oktay
Marmara University, Istanbul, Turkey
Bişra Ertas
Marmara University, Istanbul, Turkey
Ceren Ertem
Ege University, Izmir, Turkey
Claudio Ferrante
G. d’Annunzio University of Chieti-Pescara, Chieti, Italy
Derya Doğancı
Marmara University, Istanbul, Turkey
Dinesh Kumar
Indian Institute of Technology (BHU), Varanasi, India
Ebru Altuntaş
Istanbul University, Istanbul, Turkey

Enkaipasha Goci
Aldent University, Tirana, Albania
Entela Haloci
University of Medicine, Tirana, Albania
Erkan Rayman
Marmara University, Istanbul, Turkey
Guzem Tatar Yılmaz
Karadeniz Technical University, Trabzon, Turkey
Gülbahar Uçar
Hacettepe University, Ankara, Turkey
Gülgün Timuçin
Marmara University, Istanbul, Turkey
Gülşah Gedik
Trakya University, Edirne, Turkey
Hamide Serin Özbay
Hacettepe University, Ankara, Turkey
Hasan Erding Selçuk
Karadeniz Technical University, Trabzon, Turkey
İ. İrem Taḟi Çınçay
Hacettepe University, Ankara, Turkey
Karman Buran
University of Health Sciences, Istanbul, Turkey
Kılıçioğlu Othman
Aldent University, Trana, Albania
Lejla Kipo
University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Lorna Mramont
Aldent University, Tirana, Albania
Maja Ortoni Hadžidalić
University of Zagreb, Zagreb, Croatia
Mersad Kabašakal
University of Health Sciences, Istanbul, Turkey
Mehmet Sancar
Marmara University, Istanbul, Turkey
Mirza Miraj
University of Medicine, Tirana, Albania
Mohd Younas Rather
Government Medical College, Srinagar, Srinagar, India
Murat Doğan
Cumhuriyet University, Sivas, Turkey
Nurcan Tekin
University of Health Sciences, Istanbul, Turkey
Nurettin Yaşar
Karadeniz Technical University, Trabzon, Turkey
Ongun Mehmet Saka
Ankara University, Ankara, Turkey
Oya Kerimoğlu
Marmara University, Istanbul, Turkey
Pablo Minate Berra
University of Valencia, Burjaso, Spain
Pinar Talaş Pınar
Yüzyüzüncü Yıl University, Van, Turkey
Rezarta Shrinti
Aldent University, Trina, Albania
Rümeysa Keleş Kayış
Sakarya University, Sakarya, Turkey
Sasađ Solari
Istani University of Medical Sciences, Istani, Iran
Sakine Tuncay Terimverdi
Ege University, Izmir, Turkey
Simone Carradori
G. d’Annunzio University of Chieti-Pescara, Chieti, Italy
Somaiha Solari
Tabriz University of Medical Sciences, Tabriz, Iran
Tarif Catić
Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
Turgut Taşkıın
Marmara University, Istanbul, Turkey
Uğur Karazlı
Trakya University, Edirne, Turkey
Üzülay Yaman
Katılı Cesur University, Izmir, Turkey
Viktoria Makovnova
Gose Dedor University, Sip, Republic of N. Macedonia
Vildan Celiksoy
Carroll University, Carroll, UK
Yeliz Sabın
Marmara University, Istanbul, Turkey
Zahra Amer Hashimi
Mosul University, Mosul, Iraq
Züra Afthansson
Mosul University, Mosul, Iraq
Zoran Zeković
University of Novi Sad, Novi Sad, Serbia

Journal of Research in Pharmacy
An international open-access journal of pharmacy and pharmaceutical sciences
Formerly published as Marmara Pharmaceutical Journal

ONLINE SYMPOSIUM
BACTERIOThERAPY

Zahraa Amer HASHIM

Department of Microbiology and Immunology, College of Pharmacy, Mosul University, Mosul, Iraq
hashimz@uomosul.edu.iq

Humans are in symbiosis with the microbiota in the gastrointestinal tract, with over 100 trillion microbiota, including 1000 types and 1 million associated genes. Genetic analysis have shown that failure of the human-enteric symbiosis ecosystem, the so-called dysbiosis, is closely related to growing disease groups, including inflammatory bowel disease (IBD) in developed countries [1]. The change in daily habit and lifestyle have been the major contributing factors. This lifestyle refers to the inappropriate use of antibiotics, higher rate of cesarean section, artificial milk, improved hygiene, high-fat and low-fiber diet, and stress, which all can cause dysbiosis [2]. Bacteriotherapy is a treatment that prophylactically and therapeutically corrects the composition of disturbed intestinal microbiota using “good bacteria” and is a promising recent development that has been proved to be effective in managing a number of infectious diseases, cancer and psychotic and nervous disorders [3].

The worldwide emergence of bacterial resistance to antibacterial agents has produced a need for new methods of combating bacterial infections. This need is forced on us by the long time lag in developing new antibacterial agents. Even though new agents may be in the pipeline, they will not solve all current resistance problems. In addition, we also have to recognise that the use of antibacterial agents not only targets resistant bacteria but also disturbs normal human flora, which may itself further inhibit our defence against infection. Bacteriotherapy, as an alternative, has been shown effective in preventing and treating certain infections of bacterial, viral and fungal origin. Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient’s microbial composition and confer a health benefit. Borody and colleagues used FMT to treat 6 patients with refractory ulcerative colitis and follow up at 1–13 years post-FMT showed no clinical evidence of ulcerative colitis [4]. Similarly, Duplessis et al. utilized FMT to treat a patient with severe Crohn’s disease complicated by refractory CDI [5]. Obesity is another condition that could potentially benefit from FMT. FMT from lean to obese individuals led to increased insulin sensitivity in the patients compared to the control group [6].

Gut microbiome is becoming more important in the realm of cancer immunotherapy. Waves of clinical trials have been initiated to examine the clinical outcomes of modulating gut microbiota in the context of cancer therapy [7].

However, it remains challenging for bacteriotherapy to be adopted into clinical practice at this stage as little is known about its mechanism of action on modulating the immunity during cancer treatment. The proposed mechanisms by which bacteria act as anti-cancer agents have been studied and proposed to be either through enhancing human immunity, activating inflammasome pathways, CD4, CD25 and
CD8 anti-tumor effectors T cell responses, TNF-α innate immune system in bacteria-based tumor necrosis, through released substances (such as bacteriocins, biosurfactants, phenazine 1,6-di-carboxylic acid). They also act as a carrier for cancer therapeutic agents and bacteria-based microrobot (Bacteriobot) [8].

The intestinal microbiota play a relevant role in disorders of the nervous system. The microbiota–gut–brain axis may represent a new target in the prevention and treatment of neuropsychiatric disorders. Analyses of the available research results have shown that selected bacteria affect the gut–brain axis in healthy people and people with selected diseases i.e., Alzheimer’s disease, Parkinson’s disease, depression, and autism spectrum disorders and hence acquired the term “Psychobiotics” [9].

In conclusion, bacteriotherapy is an old-modern concept in the field of therapeutics showing promising findings. Bacteriotherapy is a rich field for conducting clinical research and investigations taking into consideration its potential adverse effects in the future work.

**Keywords:** Probiotics, fecal microbiota transplantation, dysbiosis, microbiota
REFERENCES


